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Abstract
Disease Overview: Cutaneous T-cell lymphomas (CTCL) are a heterogenous group of
T-cell neoplasms involving the skin, the majority of which may be classified as Myco-
sis fungoides (MF) or Sézary syndrome (SS).
Diagnosis: The diagnosis of MF or SS requires the integration of clinical and
histopathologic data.
Risk-Adapted Therapy: TNMB (tumor, node, metastasis, blood) staging remains the
most important prognostic factor in MF/SS and forms the basis for a “risk-adapted,”
multi-disciplinary approach to treatment. For patients with disease limited to the skin,
skin-directed therapies are preferred, as both disease-specific and overall survival for
these patients is favorable. In contrast, patients with advanced-stage disease with sig-
nificant nodal, visceral or blood involvement are generally approached with systemic
therapies. These include biologic-response modifiers, histone deacetylase (HDAC)
inhibitors, or antibody-based strategies, in an escalating fashion. In highly-selected
patients, allogeneic stem-cell transplantation may be considered, as this may be cura-
tive in some patients.
1 | INTRODUCTION
Primary cutaneous lymphomas are a heterogeneous group of
extranodal non-Hodgkin lymphomas which, by definition, are confined
to the skin at diagnosis. The European Organization for Research and
Treatment of Cancer (EORTC) and World Health Organization (WHO)
published a consensus classification for cutaneous lymphomas in
20051 that was recently updated.2 In contrast to nodal non-Hodgkin
lymphoma, most of which are B-cell derived, approximately 75% of
primary cutaneous lymphomas are T-cell derived, two-thirds of which
may be classified as Mycosis fungoides (MF) or Sézary syndrome
(SS).1,3,4 The incidence of cutaneous T-cell lymphomas (CTCL) has
been increasing, and is currently 6.4 per million persons, based on Sur-
veillance, Epidemiology, and End Results (SEER) registry data, with the
highest incidence rates being reported among males and African-
Americans.3 While CTCL may occur in children and young adults, this
is very uncommon and often associated with histopathologic variants
of MF.5-7 The incidence of CTCL increases significantly with age, with
a median age at diagnosis in the mid-50s and a 4-fold increase in inci-
dence appreciated in patients over 70.3,7
Epidemiological studies have failed to consistently identify environ-
mental or virally associated risk factors for most CTCL subtypes,
with the notable exception of HTLV-1 infection in adult T-cell leukemia/
lymphoma.8 Recent studies, however, have suggested that medications
may induce an antigen-driven T-cell lymphoproliferation or dyscrasia.9,10
A recent case series examined a subset of hypertensive MF patients
using hydrochlorothiazide. When compared to hypertensive MF patients
not using hydrochlorothiazide, these patients were more likely to
have stage I disease, and were less likely to have a clonal TCR gene
rearrangement.10 More importantly, in a subset of these patients, a
complete or partial response was observed upon discontinuation of
hydrochlorothiazide. In three patients, CTCL recurred upon reinitiating
hydrochlorothiazide, and subsequently receded with its discontinuation.
While these findings could be interpreted as a drug reaction, more spe-
cifically a drug-induced pseudolymphoma, the authors of this single
center study speculate that hydrochlorothiazide may be associated with
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antigen-driven T-cell lymphoproliferation and could serve as a trigger
for MF. Consequently, a therapeutic trial off hydrochlorothiazide may
be warranted in selected patients. Moreover, as a variety of other medi-
cations may initiate a reaction mimicking MF, a careful medication his-
tory should be performed in these patients with a trial off any
suspected offending drug. Individual genetic features have also been
implicated in the development of CTCL. Rare reports of familial MF,
and the detection of specific HLA class II alleles in association with both
sporadic and familial MF, suggest that host genetic factors may contrib-
ute to MF development.11-13 While the role of environmental and host
genetic factors in CTCL pathogenesis remains unclear, significant
insights into disease ontogeny, molecular pathogenesis and disease-
associated immune dysregulation have been realized.14-17 Recently per-
formed next-generation sequencing studies have demonstrated a high
frequency of C > T transitions. This is in contrast to the T > G trans-
versions observed in B-cell lymphproliferative disorders, a signature
associated with ultraviolet B (UVB) exposure in melanoma (reviewed
in 18).
The cell of origin, molecular pathogenesis, and genetic landscape
associated with MF/SS have been elucidated,19 and have significant
therapeutic implications [reviewed in18].
2 | DIAGNOSIS
2.1 | Mycosis fungoides
The definitive diagnosis of MF, particularly patch/plaque stage disease,
is challenging, as many of its clinical and pathologic features are non-
specific and overlap with reactive processes. Many patients will have
had symptoms attributed to eczema, psoriasis or parapsoriasis for years
prior to obtaining a definitive diagnosis. The median time from symp-
tom onset to diagnosis in a retrospective series is 3to 4 years, but may
exceed four decades.20-22 Given the importance of clinicopathological
correlation in the diagnosis of MF, and the variable association of spe-
cific histologic findings with the diagnosis, biopsy reports are not infre-
quently “suggestive of” the diagnosis. This occasional uncertainty
implied in biopsy reports, and apparent lack of a more definitive histo-
pathologic diagnosis, may be a source of frustration for clinicians unfa-
miliar with the challenges associated with rendering a pathologic
diagnosis of MF. Drug reactions, chronic spongiotic dermatitis, connec-
tive tissue diseases, lichen sclerosus et atrophicus, and pigmented pur-
puric dermatoses, are just a few of the conditions that may mimic
MF.23,24 Treatment with topical steroids, ultraviolet light, or systemic
immunosuppressants diminish or eliminate neoplastic T-cells and critical
histopathologic findings for 2 to 4 weeks, and patients may be receiving
these therapies at the time of biopsy. A definitive diagnosis of MF may
be made on the basis of clinical and histopathologic features alone.
However, determination of T-cell clonality and assessment for the aber-
rant loss of T-cell antigen expression by immunohistochemical staining
for CD2, CD3, CD5, and CD7, are useful ancillary studies in the diagno-
sis of MF (and SS). The PCR-based methods are able to detect clonal
rearrangements of the T-cell receptor (TCR) in formalin-fixed, paraffin-
embedded biopsy specimens.25,26 The PCR-based methods, while
sensitive, should be interpreted with caution. The clonal TCR gene
rearrangements may be detected in normal elderly individuals, and in
patients with benign dermatoses or other disease states.27-31 However,
detection of identical clones from two different sites is quite specific
for MF.32 Even this feature is not without complications. Rare reactive
processes display what appears to be an identical T-cell clone by PCR-
based gene rearrangement studies in multiple biopsies over time. The
extent to which MF/SS may be preceded by a pre-malignant state,
analogous to monoclonal B-cell lymphocytosis (MBL), or monoclonal
gammopathy of undetermined significance (MGUS), is debatable and
poorly defined.33 The malignant lymphocytes in MF/SS are usually
CD3+CD4+ and CD8−, but frequently lose the expression of other pan-
T-cell antigens. Therefore, demonstration of a significant population of
CD4+ cells lacking CD2, CD5, and/or CD7 expression is highly specific
(specificity >90%) for MF in most reported series.34,35 However, reac-
tive dermatoses may also show a predominance of CD4-positive
T-cells, and diminished expression of CD7, the T-cell antigen most fre-
quently lost in MF, and these results must be interpreted with cau-
tion.24,35 Finding a marked predominance of CD4-positive T-cells,
especially by epidermotropic T-cells, helps to support a diagnosis of
MF.24,35 Similarly, finding extensive loss of CD7, preferential loss of pan
T-cell antigens by epidermal T-cells, or loss of multiple pan T-cell
markers favors a diagnosis of MF in challenging cases.24,35 Clinically,
patch/plaque stage MF is frequently characterized by persistent and
progressive lesions that develop in a “bathing suit” distribution and vary
in size, shape and color. These lesions are frequently large (>5 cm),
pruritic and multifocal in “classical” MF. However, a broad range of MF
variants have been described with differences in tropism (eg, follicular
MF), distribution (eg, palmoplantar MF), pigmentation (eg, hypo- and
hyperpigmented variants) and focality (eg, unilesional MF), some of
which are formally recognized in the WHO-EORTC classification.1,36
Histopathologically, patch/plaque MF is characterized by enlarged,
epidermotropic lymphocytes, with irregular nuclei that often show a
band-like distribution in the dermis, where they are associated with
dense strips of collagen (“wiry” fibrosis). Aggregates of neoplastic T-cells
in the epidermis, termed Pautrier microabscesses, are seen in a minority
of cases, but are a helpful clue to the diagnosis. Folliculotropism and/or
syringotropism may be seen in a minority of cases. Given the need for
uniform diagnostic criteria in MF, the International Society for Cutane-
ous Lymphoma (ISCL) recently proposed a point-based diagnostic algo-
rithm which integrates clinical, histopathologic and immunophenotyping
data with an assessment of T-cell clonality.23
2.2 | Sézary syndrome
Traditionally, SS is defined as a leukemic form of CTCL associated with
erythroderma. A series of studies in the early to mid-20th century,
beginning with Sezary's initial landmark observation in 1938, identified a
population of large lymphocytes in the peripheral blood with grooved,
lobulated (ie, “cerebriform”) nuclei in patients with MF or SS.37-42 As in
other chronic lymphoproliferative disorders, the Sezary cell count is
preferably expressed in absolute terms. That is with ≥1000 cells/μl
classified as B2 disease in the current ISCL/EORTC TNMB staging
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classification. The morphologic detection of Sezary cells in the peripheral
blood is not specific for CTCL, as Sezary cells may be found in peripheral
blood from normal donors and in benign conditions.43-45 The histopath-
ologic findings in the skin often resemble those observed in MF, with
less prominent epidermotropism, though findings in skin biopsies may
be paradoxically subtle and non-specific. As in MF, immunohistochemi-
cal studies showing a CD4 predominance and loss of pan T-cell markers
may be helpful. Lymph node involvement is characterized by complete
effacement of the nodal architecture by infiltrating Sezary cells.46
In SS, clonal T cells are generally CD3+CD4+ and CD8− by multi-
color flow cytometry.47-50 As in MF, the aberrant loss of pan-T-cell
antigens, including CD2, CD3, CD4, CD5, CD7 and/or CD26 is fre-
quently observed.49,51-54 Of these, the aberrant loss of CD7 and/or
CD26 expression is most common, being observed in most
cases.50,51,55-59 The loss of CD7 (≥40%) and/or CD26 (≥80%) is sensi-
tive (>80%) and highly specific (100%) for SS.54 The aberrant expression
of the MHC class I-binding, killer immunoglobulin-like receptor (KIR)
CD158κ (and less commonly CD158a or CD158b), normally expressed
by natural killer cells, was described in the majority of patients exam-
ined with SS.54,60,61 Molecular studies, including detection of a clonal
TCR gene rearrangement by PCR and the presence of a clonal cytoge-
netic abnormality, provide evidence of T-cell clonality. An alternative
approach to demonstrate T-cell clonality incorporates multi-color flow
cytometry, using a panel of antibodies specific for various TCR beta-
chain variable region family members (TCR-Vβ).62-64 This approach is
successful in identifying a clonal population of T cells if this population
is significantly higher than the background frequency of polyclonal T
cells harboring the same Vβ chain.62,63
The currently proposed ISCL criteria for SS integrate clinical, histo-
pathologic, immunophenotyping and molecular studies. In patients with
erythroderma, criteria recommended for the diagnosis of SS by the
ISCL include the following: absolute Sezary count ≥1000/μl, a
CD4/CD8 ratio ≥10 (due to the clonal expansion of CD4+ cells), aber-
rant expression of pan-T-cell antigens, demonstration of T-cell clonality
by Southern blot or PCR-based methods, or cytogenetic demonstration
of an abnormal clone.49 At a minimum, the WHO-EORTC recommends
the demonstration of T-cell clonality in combination with the above-
mentioned criteria for the diagnosis of SS.1 In addition to the ISCL
criteria, the most recent WHO classification requires erythroderma,
generalized lymphadenopathy, and clonally related T-cells (Sézary cells)
in the skin, peripheral blood, and lymph nodes. On rare occasions, SS
may be preceded by a prior history of classic MF. The ISCL recom-
mends that such cases be designated as “SS preceded by MF.” Con-
versely, patients with MF, but without erythroderma, may meet
hematologic criteria for SS. In these cases, the designation “MF with
leukemic involvement” is recommended.
2.3 | Non-MF/SS subtypes of CTCL
An important goal during a patient's initial diagnostic evaluation is to
distinguish non-MF/SS CTCL subtypes from MF/SS, as the natural
history, prognosis, and treatment approach for each of the non-
MF/SS lymphomas is highly variable. A detailed description of these
CTCL subtypes is beyond the scope of this update, but the salient fea-
tures of each have been previously summarized.2,65
3 | RISK STRATIFICATION
3.1 | Staging
In contrast to many other lymphoproliferative disorders in which cyto-
genetic and laboratory findings play a prominent role in risk stratifica-
tion, TNMB (tumor, node, metastasis, blood) staging remains an
important prognostic factor in MF/SS, and forms the basis for a “risk-
adapted” approach to treatment. In 2007, the ISCL and EORTC revised
the TNMB staging of MF/SS.66 Patients with only patches and plaques
have stage I disease, but may be further divided into stage IA (<10%
body surface area involved or T1) or stage IB (>10% body surface area
involved or T2) based on the extent of skin involvement, and by the
presence of patch- (T1a/T2a) or plaque-stage (T1b/T2b) disease. For
practical purposes, the area of one hand (including both palm and digits)
represents approximately 1% of body surface area. Current staging and
diagnostic recommendations do not require a biopsy of clinically normal
lymph nodes. However, an excisional biopsy of any abnormal lymph
nodes (≥1.5 cm in diameter or firm/fixed) is recommended. Preference
is given either to the largest lymph node draining an area of skin
involvement, or to the node with the greatest standardized uptake
value (SUV) on FDG-PET imaging.67-69 Patients with patch/plaque
stage disease (T1/T2), and architectural preservation of any clinically
abnormal lymph nodes are classified as stage IIA. Collectively, patients
with stage I-IIA disease have “limited (or early)-stage” disease, as the
overall survival in these patients is measured in decades, with survival
in patients with stage IA disease resembling that of normal age-
matched controls.7,20,21 At diagnosis, the majority of MF patients will
have limited-stage disease.7 In contrast, patients with tumor stage dis-
ease (T3), erythroderma (T4), nodal involvement characterized by partial
or complete architectural effacement (N3), visceral metastases (M1), or
significant leukemic involvement (B2) have “advanced” or late “late-
stage” disease. Detection of a clonal TCR gene rearrangement by PCR,
which has been incorporated into the revised ISCL/EORTC node(N)
and blood(B) staging classification, is an adverse prognostic factor.7,70-73
Unfortunately, median survivals from approximately 1 to 5 years are
observed in these patients with more extensive disease.7 The revised
ISCL/EORTC staging for MF/SS is summarized in Table 1.
A retrospective study including 1398 MF patients, 71% with pat-
ch/plaque stage disease, and 104 SS patients has validated the revised
ISCL/EORTC staging classification.7 On univariate and multivariate ana-
lyses, the revised T, N, M and B classification were significantly associ-
ated with overall and disease-specific survival. The median survival,
disease-specific survival and risk of disease progression, by clinical
stage, are summarized in Table 1. For those with early-stage disease,
male gender, age > 60, plaque-stage or folliculotropic disease, and
nodal stage N1/Nx were adverse prognostic factors and were utilized
to generate the cutaneous lymphoma international prognostic index
(CLIPi) for patients with early-stage disease.74 Ten-year OS was 90.3%
for those with low-risk (0-1 risk factors) disease, and 48.9% for those
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with high-risk (3-5 risk factors) disease. Similarly, male gender, age > 60,
stage B1/B2 or N2/N3 disease, and visceral involvement were adverse
prognostic factors for patients with late-stage disease. Ten-year OS
was 53.2% for low-risk patients, and 15.0% for high-risk patients.74 In a
large, international series (n = 1275) of late-stage MF/SS, stage IV dis-
ease, age > 60, large-cell transformation, and elevated LDH were iden-
tified as independent adverse prognostic factors, and were similarly
combined in a prognostic index.75 Patients with low-risk (0-1 risk fac-
tors) disease experienced superior 5-year OS (68%), compared with the
5-year OS observed (28%) among those with high-risk (3-4 risk factors)
disease.7,76-80 Given the importance of the TNMB classification in risk
stratification and defining disease burden, the ISCL/EORTC recom-
mends its use in defining the initial, maximum and current burden of
disease, which will ultimately play an important role in the selection of
either skin-directed or systemic therapies.66 In the future, it is antici-
pated that improved understanding of the genetic landscape will fur-
ther improve risk-stratification and lead to a more personalized
approach for treatment selection in CTCL.18
Recognizing that the staging system used for MF/SS is less helpful
for non-MF/SS cutaneous lymphomas, a new TNM classification was
also proposed for these CTCL variants.81 Due to the significant het-
erogeneity of these lymphomas, this staging system does not provide
prognostic information, but is intended to provide a uniform descrip-
tion of the disease burden.
4 | TREATMENT OF LIMITED-STAGE MF
As the majority of CTCL patients present with patch/plaque stage MF
and have an excellent prognosis, the initial goal of therapy is to improve
symptoms and quality of life while avoiding treatment-related toxicity.
For many patients, this may involve either expectant management (ie,
“watch and wait”) or skin-directed therapies. A randomized trial com-
pared early combined modality therapy, including both radiation and
multi-agent chemotherapy (cyclophosphamide, doxorubicin, etoposide,
and vincristine), with sequential topical therapies. It demonstrated that
combined-modality therapy, while associated with a superior complete
response rate, did not translate into improvements in disease-free or
overall survival, and was associated with significant toxicity.82 The lim-
ited efficacy associated with chemotherapy has been highlighted in ret-
rospective studies in which the median time to next treatment
following single or multiagent chemotherapy was ≤4 months.83,84
Therefore, patients with limited-stage disease who require therapy are
best approached with skin-directed therapies, usually under the direc-
tion of a dermatologist and/or radiation oncologist. Excellent reviews
and treatment guidelines are available.65,85-90
4.1 | Topical therapies
The first-line treatment for limited stage MF is topical steroids. In an
uncontrolled prospective study, topical clobetasol propionate was used
in 85% of patients with stage 1A/B disease, had an overall response
rate (ORR) of 94%, and is associated with minimal to no toxicity.91,92
An alternative topical medication is mechlorethamine 0.02% gel. In a
phase 2 trial, patients with stage IA-IIA MF were treated with 0.02%
gel daily for up to 12 months. A response was observed in 58.5% of
patients, with 13.8% achieving a complete response. A sustained
response was observed in 85.5% patients, and the most common
adverse effects are contact dermatitis and irritant dermatitis.93 For
refractory and persistent cutaneous lesions, bexarotene 1% topical gel
may be considered. Prospective trials have demonstrated an ORR
between 44% and 63%.94 Topical toll-like receptor (TLR) agonists,
which lead to local production of interferons, and other cytokines,
induce cell death and promote host anti-tumor immunity,95 and have
demonstrated efficacy in limited stage MF. For example, 20 patients
with stage 1A-2B disease were treated with 5% imiquimod, a TLR7
agonist. An ORR of 80%, including 45% complete responses, was
observed. Toxicities are limited, including localized pain, redness, ulcer-
ation, and pruritus. Systemic symptoms, including flu-like symptoms
and fatigue, while reported, are rare. Most adverse events are self-lim-
ited, and resolve after the first few weeks of treatment.95,96
Resiquimod, a potent TLR7/8 agonist, was examined in a phase 1 trial
using 0.03% and 0.06% topical resiquimod gel. Among the 12 patients
treated, clinical improvement was observed in 75% of treated lesions,
and 90% of patients had a reduction in malignant T-cell clones in the






T N M B OS (%) DSS (%) RDP (%)
IA 1 0 0 0,1 35.5 88 95 12
IB 2 0 0 0,1 21.5 70 77 38
IIA 1, 2 1 0 0,1 15.8 52 67 33
IIB 3 0-2 0 0,1 4.7 34 42 58
IIIA 4 0-2 0 0 4.7 37 45 62
IIIB 4 0-2 0 1 3.4 25 45 73
IVA1 1-4 0-2 0 2 3.8 18 20 83
IVA2 1-4 3 0 0-2 2.1 15 20 80
IVB 1-4 0-3 1 0-2 1.4 18 (5 years) 18 (5 years) 82 (5 years)
Abbreviations: OS, overall survival; DSS, disease-specific survival; RDP, risk of disease progression.
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treated lesions, and an abscopal, and presumably immune-mediated,
effect was observed.97
4.2 | Phototherapy
Phototherapy is an important treatment modality that may be used
alone, or in combination with topical therapies, in patients with
limited-stage disease, and includes narrowband UVB (NBUVB,
311 nm), and 8-methoxypsoralen plus ultraviolet A (PUVA). Narrow
band UVB is used in both patch and plaque stage MF, PUVA is the
modality of choice in skin of color. Phototherapy is widely available
and has demonstrated efficacy in many retrospective and prospective
studies,98,99 and a comprehensive consensus statement on the use of
phototherapy was recently published.100
4.3 | Radiation
The MF/SS are radiosensitive, thus radiation therapy, with curative
intent, may be considered in patients with localized, unilesional
MF. For those with more widespread disease, palliative local radiation
or low-dose total skin electron beam therapy (TSEBT) are effective
[reviewed in, 101,102].
5 | TREATMENT OF ADVANCED-
STAGE MF/SS
5.1 | Overview
Patients with advanced-stage MF/SS require a multidisciplinary
approach, as various combinations of skin-directed therapies, biologic-
response modifiers and ultimately the sequential use of systemic che-
motherapeutic agents, are frequently employed in the management of
these patients. As for limited-stage disease, multi-agent chemotherapy,
with only few exceptions, is generally not appropriate.82 A “risk-adapted”
stage-based approach, consistent with NCCN guidelines, is adopted. This
is done with biologic-response modifiers (eg, bexarotene and interferon-
alpha), and histone deacetylase (HDAC) inhibitors (eg, romidepsin,
vorinostat), generally preferred prior to escalating therapy to include sys-
temic chemotherapy.103 Therapeutic decisions are individualized and
based on a patient's age, performance status, extent of disease burden,
the rate of disease progression, and previous therapies.85-90
5.2 | Bexarotene
The endogenous retinoids all-trans retinoic acid and 9-cis retinoic acid
(ie, vitamin-A-derived compounds) regulate a diverse array of biologic
processes. They range from embryonic development to cell growth, dif-
ferentiation and survival, upon binding two families of steroid hormone
receptors; the retinoic acid receptors (RAR) and retinoid X receptors
(RXR). Upon forming homo- or heterodimers, these receptors recruit
various nuclear co-repressor or co-activator proteins depending
whether or not they are bound by ligand. Multiple RAR retinoids have
been used in MF/SS, either topically or systemically (reviewed in,104,105
with response rates exceeding 50%. However, in 1999 the oral RXR-
selective “rexinoid” bexarotene was FDA approved for CTCL, and was
later approved as a topical gel formulation. Laboratory studies demon-
strate that bexarotene promotes cell cycle arrest and apoptosis in CTCL
cell lines.106,107 In a multicenter phase II-III study, there were 94 patients
with advanced-stage CTCL who had been previously treated with a
median of five prior therapies. The vast majority had disease refractory
to at least one prior systemic therapy, and they received at least
300 mg/m2 of oral bexarotene daily.108 Among patients treated at the
300 mg/m2 dose, an ORR of 45% was observed, only 2% of which were
complete. While an improved ORR was noted with the use of higher
doses, this difference was not statistically significant, and dose-limiting
toxicity was far more common (50% vs 89%) in these patients. While a
dose-response relationship is likely, the 300 mg/m2 dose appears to
provide the optimal risk-benefit ratio. The most common toxicities asso-
ciated with therapy were hypertriglyceridemia (in 82%) and central
hypothyroidism (29%). Myelosuppression is infrequent and usually
uncomplicated. Pancreatitis secondary to hypertriglyceridemia may be
rarely observed, but is reversible upon discontinuation of treatment.
Therefore, a baseline lipid panel and free T4/TSH should be obtained
prior to the initiation of therapy. In one retrospective study, all patients
treated with bexarotene developed hyperlipidemia and central hypothy-
roidism, frequently within weeks of initiating treatment.109 Conse-
quently, use of lipid-lowering agents (eg, fenofibrate) and low-dose
levothyroxine (eg, 50 micrograms) prior to initiating bexarotene is gener-
ally recommended.110-112 In clinical practice, bexarotene is frequently
initiated at a lower dose of 150 mg/m2, and subsequently titrated to full
doses after 4 weeks of therapy, depending upon patient tolerability.
Most responses occur within 2 to 3 months of treatment initiation, but
may be delayed. Therefore, in the absence of disease progression or
toxicity, treatment should be continued for up to 6 months. For
responding patients, treatment should be continued until disease pro-
gression, and depending upon the quality of the response, adjunctive
skin-directed therapies (eg, PUVA, interferon) should be considered.113
Guidelines describing appropriate laboratory monitoring, supportive
care, and safe clinical prescribing of bexarotene have been recently pub-
lished.112 Future studies clarifying the optimal use of bexarotene, either
in combination or sequentially with other agents, are needed.
5.3 | HDAC inhibitors
HDACs catalyze the removal of acetyl groups from both histone and
non-histone proteins. As histone acetylation is associated with an open
chromatin configuration associated with active gene transcription,
HDACs contribute to histone deacetylation and the epigenetic repres-
sion of gene transcription. As HDACs regulate a wide variety of pro-
cesses involved in carcinogenesis, multiple mechanisms may explain the
clinical activity of HDAC inhibitors.114,115 Those include altered gene
expression of cell-cycle and apoptotic regulatory proteins,116-120 acety-
lation of non-histone proteins regulating cell growth and survival,121-124
angiogenesis,125,126 aggresome formation127 and DNA repair.128 In
addition, HDAC inhibitors may have important effects on the tumor
microenvironment via reactive oxygen species,129,130 enhanced antigen
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presentation131 and downregulation of immunomodulatory cytokines,
like IL-10.132
Vorinostat (suberoylanilide hydroxamic acid, SAHA) and romidepsin
(depsipeptide) inhibit class I and II HDACs (ie, pan-HDAC inhibitors),
the former being widely expressed in various lymphoma subtypes.133
Early phase I studies of both vorinostat and romidepsin established
their safety and potential efficacy in lymphoproliferative disorders,
including CTCL,134 thus paving the way for larger phase II studies. An
earlier phase II study established 400 mg of oral vorinostat once daily
as the optimal dose that was investigated further in 74 previously
treated patients with CTCL, most of whom (>80%) had advanced-stage
disease.135,136 The ORR was approximately 30% for patients with
advanced-stage disease, and was associated with a median duration of
response estimated to exceed 185 days. Most responses were rapid (ie,
<2 months), and were also noted in patients with tumor-stage disease
and SS.137 Patients who failed to achieve an objective response
appeared to derive some clinical benefit, including stable disease,
decreased lymphadenopathy and pruritis relief, with treatment. The
most common non-hematologic adverse events, observed in almost
50% of patients, were gastrointestinal toxicities (nausea, vomiting, and
diarrhea). Hematologic toxicities, including anemia or thrombocytope-
nia, were observed in up to 20% of patients. Among responding
patients, long-term therapy with vorinostat appears to be well toler-
ated.138 Prolongation of the QT interval was rarely observed, but moni-
toring and appropriate electrolyte replacement is recommended for
those patients at risk for QT prolongation.139
Romidepsin, administered as a four-hour intravenous infusion
(14 mg/m2) days one, eight and 15 every 4 weeks, was evaluated in two
phase II studies, the largest of which included 96 patients, most with
advanced-stage disease.140,141 The ORR was 38% for patients with
advanced-stage disease, with a median duration of response that
exceeded 1 year. A toxicity profile similar to that described for vorinostat
was observed. Intensive cardiac monitoring in a subset of these patients
failed to demonstrate any clinically significant cardiotoxicity.142 A subset
of MF/SS patients, after induction with romidepsin at the standard dose,
may anticipate a durable remission with attenuated “maintenance” (every
two or four-weeks) dosing. For example, among 38 MF/SS patients,
17 achieved a durable (>6 months) remission, nine of which were
maintained with an attenuated, dose-sparing schedule.143 Among the
patients achieving a durable remission, the median duration of treatment
was 15 months (range: 7-34 months).
Additional HDAC inhibitors, including potent pan-HDAC inhibi-
tors, appear to have activity in CTCL.120,144,145 Further studies are
needed to fully define the mechanisms of resistance to HDAC inhibi-
tion in CTCL,120,146-150 enabling the development of rational thera-
peutic combinations incorporating HDAC inhibitors in CTCL.151,152
5.4 | Interferon-alpha
Interferon-alpha (ie, interferon-alpha 2b), a type I interferon with
immunomodulatory properties, has pleiotropic effects in CTCL, and is
associated with an ORR of 50%-70%. It has a complete response rate
of 20%-30%, particularly in patients with limited-stage disease.153-156
While often considered as second-line therapy for limited-stage CTCL,
interferon-alpha, frequently at doses ranging from 3-10 million units
daily to three times weekly, is a treatment to be considered in the first-
line setting in patients with advanced-stage disease. Responses, which
may be achieved within a few months, are observed in patients with
tumor-stage MF and SS, and are occasionally durable.83,157 Further-
more, interferon-alpha may be successfully combined with a number
of other therapeutic modalities frequently utilized in the management
of these patients, including PUVA, bexarotene, chemotherapy and
ECP.158-171 For example, in a cohort of 51, mostly advanced-stage
patients treated with single-agent, low-dose, interferon-alpha, responses
were observed in 34 (67%), including 21 (41%) with a complete
response, and nine with a long-term remission.156 Similarly, in a cohort
of 47 patients with stage III/IV disease, 89% of whom had peripheral
blood involvement, a response rate exceeding 80% was observed in
those treated with a combination of ECP and interferon-alpha.171
Interferon-alpha is associated with myelosuppression, transaminitis and
dose-limiting flu-like side effects, particularly at higher doses.
5.5 | Extracorporeal photophoresis (ECP)
During ECP, pooled leukapheresis and plasmapheresis products are
exposed to 8-methoxypsoralen (8-MOP), prior to extracorporeal circu-
lation through a 1 mm thick disposable cassette exposed to UVA radi-
ation. The irradiated leukocytes, representing approximately 5% of
peripheral blood leukocytes, are subsequently reinfused. Psoralen
covalently binds and crosslinks DNA following UVA exposure, leading
to the induction of apoptosis in the majority of treated lymphocytes
by multiple mechanisms involving bcl-2 family members, disruption of
the mitochondrial membrane potential and extrinsic cell death path-
ways.172-174 In contrast, ECP leads to monocyte activation, including
significant changes in gene expression,175 and dendritic cell differenti-
ation, which is thought to culminate in enhanced antigen presentation
and the initiation of a host immune response.176
Following the landmark study by Edelson and colleagues describ-
ing responses in 27 out of 37 patients with erythrodermic CTCL
treated with ECP, it was approved by the Food and Drug Administra-
tion of the USA for the treatment of CTCL. It is now considered the
treatment of choice in the first-line management of patients with SS
in many centers.177 Furthermore, retrospective series demonstrate
that ECP is associated with superior time to next treatment, when
compared with most systemic therapies, including HDAC inhibitors.84
While responses vary between case series, ORRs hover around 60%,
with a complete response rate of approximately 20%.178-181 As cur-
rent treatment protocols no longer require the oral administration of
8-MOP, eliminating nausea, ECP is safe and generally very well toler-
ated. Long-term use of ECP may cause iron deficiency anemia due to
the small residual blood volume that is not returned to the patient.182
While alternative schedules have been investigated, ECP is generally
performed for two consecutive days every 4 weeks, although alterna-
tive schedules have been adopted at some centers. While the precise
mechanism of action is incompletely understood, evidence suggests
that ECP has immunomodulatory effects which may augment host
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anti-tumor immunity. It is not surprising then that the median time to
response following the initiation of ECP is approximately 6 months.
Median survival exceeding 8 years has been observed in ECP treated
patients and among complete responders, many experience durable
responses which may permit, for some, weaning from CTCL-directed
therapies.178,183-185 While patient- or disease-specific factors which may
predict a response to therapy are imperfect, patients for whom treat-
ment is initiated promptly after diagnosis who have circulating Sézary
cells, but without significant nodal or visceral disease, may be more likely
to respond. In addition, patients without profound immune deficiencies,
reflected by normal or near-normal cytotoxic T-cell and CD4/CD8
values, and the absence of prior exposure to systemic chemotherapy,
may be more likely to respond to therapy.178,180,184 While effective as
monotherapy, ECP has also been combined with other therapeutic strat-
egies, including interferon, bexarotene and TSEBT.161,171,183,186-188
5.6 | Monoclonal antibodies and immunotoxins
In contrast to many B-cell lymphoproliferative disorders, where the
incorporation of CD20-targeting monoclonal antibodies has become
the standard of care, additional studies are needed to identify the opti-
mal approach targeting T-cell specific antigens in advanced-stage
MF/SS. Alemtuzumab is a humanized IgG1 monoclonal antibody
directed against CD52, an antigen widely expressed by B-cells, T-cells
and monocytes.189 In a phase II study in 22 patients with advanced-
stage MF/SS, overall and complete response rates of 55% and 32%,
respectively, were observed, with a median time to treatment failure of
1 year.190 Given the significant risk of infectious complications, low-
dose subcutaneous alemtuzumab was investigated in 14 patients with
SS, most of whom had relapsed/refractory disease.191 Most patients in
this study received 3 mg of subcutaneous alemtuzumab on day
1, followed by a 10 mg dose on alternating days until the Sézary count
was <1000/mm3. With the exception of a single patient whose best
response was stable disease, 9 out of 10 patients treated in this manner
achieved a response, three of which were complete. For most patients,
the time to treatment failure exceeded 12 months. What is notable,
however, is that infectious complications were not observed in patients
treated with the lowest dose (ie, 10 mg) of alemtuzumab. Similar
results, with no infectious complications, were recently reported in a
small cohort of patients treated with modified, low-dose, subcutaneous
alemtuzumab for 6 weeks.192 In addition to hematologic toxicity, con-
ventionally dosed alemtuzumab in advanced-stage MF/SS is associated
with a high incidence of infectious complications.190,191,193-196 Overall,
infectious complications have been observed in two-thirds of treated
patients, most of which are bacterial, including sepsis. Cytomegalovirus
(CMV) reactivation is the most common viral infection. In addition,
Pneumocystis jirovecii pneumonia and invasive fungal infections have
also been observed. Therefore, trimethoprim-sulphamethoxazole and
acyclovir should be routinely administered for PJP and HSV/VZV pro-
phylaxis, respectively, in patients receiving alemtuzumab. In addition,
CMV surveillance should be performed every 1 to 2 weeks by quantita-
tive PCR, and suppressive therapy with ganciclovir or oral valganciclovir
initiated in response to viral reactivation. Low-dose, subcutaneous
alemtuzumab appears to be safe and efficacious in selected patients
with advanced-stage MF/SS provided with appropriate supportive care.
Monoclonal antibodies targeting additional T-cell specific antigens,
including CD2,197 CD4,198 CD25199 and CCR4200-202 are being
explored and appear promising. Resimmune, a second-generation
immunotoxin in which the catalytic and translocation domains of diph-
theria toxin (DT390) have been fused to CD3-specific single chain anti-
body fragments [bisFv(UCHT1)], is associated with a response rate of
36% (16% complete), and is particularly active in patients with limited-
stage disease.203 Much like its predecessor, resimmune is associated
with a vascular leak syndrome.65
5.7 | Mogamulizumab
Mogamulizumab (KW-0761) is a humanized monoclonal antibody specific
for the chemokine receptor CCR4 that has been defucosylated and
is consequently associated with enhanced antibody-dependent cell-
mediated cytotoxicity (ADCC). In a phase I/2 study, mogamulizumab was
well tolerated and was associated with an ORR of 37%. A similar
response rate of 29% (2/7), all partial, was observed in a phase II Japanese
study.202,204 In addition to ADCC-mediated clearance of malignant T cells,
mogamulizumab may inhibit Treg-mediate immune suppression,
205,206
and may warrant further investigation with immunomodulatory thera-
pies, including immune checkpoint blockade (CPB).207 A randomized,
phase III clinical trial comparing mogamulizumab and vorinostat in
relapsed/refractory CTCL (MAVORIC) demonstrated a significant
improvement in progression-free survival among MF/SS patients ran-
domized to mogamulizumab.208 Overall responses in patients treated
with mogamulizumab were higher in the blood compartment (68%)
when compared with those observed in the skin (42%) or lymph nodes
(17%). Not surprisingly then, the ORR was highest among Sezary syn-
drome (SS) patients (37%). Overall, treatment with mogamulizumab was
well tolerated, with few ≥grade 3 adverse events (AE's). Infusion-related
reactions were the most common grade 1 or 2 AE's and were observed
in 32%. These positive findings led to mogamulizumab's approval by
the FDA in 2018 for MF/SS patients who have failed at least one prior
systemic therapy.
5.8 | Brentuximab vedotin
Given the promising response rates observed with brentuximab
vedotin (BV) in phase II studies,209-211 a randomized, phase III clinical
trial (ALCANZA) comparing BV with an investigator's choice (metho-
trexate or bexarotene) was performed, and demonstrated a signifi-
cantly improved PFS (>12 months vs 3.5 months) for patients
randomized to BV, and led to its FDA approval in previously treated
CTCL.212 Among MF patients with limited-stage disease treated with
BV, a response lasting at least 4 months (ORR4) was observed in 40%,
whereas an ORR4 of 63% was observed among patients with tumor-
stage (stage IIB) disease. Consistent with prior experience in “CD30
high” lymphomas, an ORR4 of 89% was observed among patients with
primary cutaneous ALCL with disease confined to the skin.
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5.9 | CPB
Durable remissions may be achieved with immunomodulatory therapies,
including ECP and interferon-α. While largely anecdotal, these observa-
tions suggest that host immunity, when properly harnessed, can lead to
durable responses in selected patients. These observations, coupled with
high-level PD-L1 expression in a substantial minority of patients, provide
a strong rationale for CPB in CTCL.213,214 While few CTCL patients have
been included in early phase clinical trials, durable responses have been
observed, including two responding CTCL patients who achieved
responses that were ongoing at 24+ and 50+ weeks.215 Preliminary
data from an ongoing phase II study with pembrolizumab in relapsed/
refractory MF and SS appears similarly promising. There is an ORR of
33% in MF/SS, including in patients with advanced-stage disease.214
These encouraging preliminary results, in conjunction with the smorgas-
bord of currently available immunomodulatory agents, including HDAC
inhibitors, may lend themselves to future combinatorial strategies.214
5.10 | Systemic chemotherapy
Responses to conventional chemotherapeutic agents are rarely dura-
ble in CTCL,65 being associated with a median time-to-next treatment
that is measured in months.83,84 Consequently, >90% of patients
treated in this manner will require additional therapy within the first
year of therapy. Furthermore, first-line treatment with systemic che-
motherapy has been associated with increased mortality.216 There-
fore, multi-agent chemotherapy is rarely utilized, and is generally
reserved for patients with bulky and rapidly progressive disease.
Therefore, novel therapeutic agents, including clinical trial participa-
tion, are preferred. As there is no standard of care for patients with
MF/SS requiring systemic chemotherapy and the decision to initiate
therapy is individualized, including consideration of responses and
complications related to prior therapies, participation in a well-
designed clinical trial is always worth consideration.
Pralatrexate, a novel antifolate with a high affinity for the reduced
folate carrier (RFC-1) and novel mechanism of resistance when com-
pared with methotrexate,217-219 was associated with an ORR of 29% in
the PROPEL study. This study was comprised largely of peripheral T-cell
lymphoma patients, most of whom had refractory disease.220 Notably,
12 patients with transformed MF were included in the study.221 Many
of these patients had received more than five prior systemic therapies,
including CHOP or CHOP-like regimens. With only a single exception,
these patients were refractory to their most recent therapy. Responses,
as assessed by the study investigators, were observed in 58% of
patients with a median duration of response and progression-free sur-
vival of 4 to 5 months. Results of a dose-finding study were reported in
a larger cohort of CTCL patients.222 In this study, the optimal dose was
identified as 15 mg/m2, given weekly 3 weeks out of 4, and was associ-
ated with an ORR of 43%. In an effort to reduce the incidence of
mucositis, folic acid and vitamin B12 supplementation is routinely pro-
vided in these patients.223 Additional therapeutic approaches, including
proteasome inhibition,224 immunomodulatory strategies,225 and more
targeted approaches warrant further investigation.226,227
5.11 | High-dose chemotherapy and hematopoietic
stem cell transplantation
The available experience with high-dose chemotherapy and autologous
stem cell transplantation, largely confined to case series, suggests that
responses following treatment are frequently transient. In contrast, the
durable remissions observed following allogeneic transplantation
may be explained by the graft vs lymphoma immune response.228,229
A retrospective analysis of 60 patients with advanced-stage MF/SS
who underwent allogeneic stem cell transplantation was recently
reported.230 In this series, patients had received a median of four prior
therapies prior to undergoing either reduced-conditioning (73%) or
myeloablative (27%) conditioning, prior to related (75%) or matched-
unrelated donor (25%) transplantation. Non-relapse mortality at 1 year
was 14% for patients receiving reduced-intensity conditioning or HLA
identical/related donor stem cells and 38-40% for those undergoing
myeloablative conditioning or receiving match-unrelated donor grafts.
Transplantation during an early phase of disease (defined as first or sec-
ond remission or relapse following three or fewer systemic therapies)
was associated with lower relapse rates (25% vs 44% at 1 year), and a
statistically insignificant increase in three-year overall survival (68% vs
46%). Given the differences in non-relapse mortality, both reduced-
intensity conditioning and use of matched-related donors were associ-
ated with superior overall survival (63% at 3 years). Seventeen out of
26 patients who relapsed received donor-lymphocyte infusions. Of
these, 47% achieved a complete remission, thus providing evidence for
a graft-vs-lymphoma effect in MF/SS. The estimated three-year
progression-free and overall survival were 34% and 53%, respectively.
In a larger series from the CIBMTR (n = 129), non-relapse mortality and
disease progression at 1 year were 19% and 50%, respectively, and
5 years PFS and OS were 17% and 32%, respectively.231 Given the
possibility of complete and durable remissions, allogeneic stem-cell
transplantation may be considered in highly selected patients.157,232,233
6 | SUMMARY
Establishing a definitive diagnosis of CTCL, accurate disease staging
and risk-stratification, and the selection of appropriate therapy requires
a multidisciplinary approach. While high response rates may be
achieved with systemic chemotherapy, these responses are frequently
short-lived and associated with significant toxicities. As treatment of
advanced-stage MF/SS is largely palliative, a stage-based approach uti-
lizing sequential therapies in an escalated fashion is preferred. Participa-
tion in a well-designed clinical trial is encouraged, as the introduction of
novel agents will continue to expand the therapeutic options available
in the management of CTCL.
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